Visual hallucinations in progressive supranuclear palsy [3]

European Neurology

Volumn 54, Issue 4, 2006, Pages 217-219

  Papapetropoulos, Spiridon ^a   Mash, Deborah C ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMFEBUTAMONE; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; RISPERIDONE; SELEGILINE; ZOLPIDEM;

AGED; AUDITORY HALLUCINATION; CLINICAL ARTICLE; DAYTIME SOMNOLENCE; DEMOGRAPHY; DISEASE DURATION; DISEASE EXACERBATION; ENVIRONMENTAL EXPOSURE; FEMALE; HIPPOCAMPUS; HUMAN; LETTER; MALE; MEDICAL RECORD; MINI MENTAL STATE EXAMINATION; MOTOR DYSFUNCTION; PARKINSONISM; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PSYCHOMETRY; QUESTIONNAIRE; SLEEP DISORDER; VISUAL HALLUCINATION; WHITE MATTER;

AGED; FEMALE; HALLUCINATIONS; HUMANS; MALE; MIDDLE AGED; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 31744433213     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090713     Document Type: Letter

References (13)

1. Steele JC, Richardson JC, Olszewski J: Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964;10:333-359.
2. Papapetropoulos S, Gonzalez J, Mash DC: Natural history of progressive supranuclear palsy. A clinicopathologic study from a population of brain donors. Eur Neurol 2005;54: 1-9.
3. Aarsland D, Litvan I, Larsen JP: Neuropsychiatrie symptoms of patients with progressive supranuclear palsy and Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001;13:42-49.
4. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS: Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47: 1-9.
5. Folstein MF, Folstein SE, McHugh PR: 'Minimental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
6. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). 2. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486.
7. Litvan I, Agid Y, Jankovic J, Goetz C, Brandel JP, Lai EC, Wenning G, D'Olhaberriague L, Verny M, Chaudhuri KR, McKee A, Jellinger K, Bartko JJ, Mangone CA, Pearce RK: Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology 1996;46: 922-930.
8. Papapetropoulos S, Mash DC: Psychotic symptoms in Parkinson's disease. From description to etiology. J Neurol 2005;252:753-764.
9. Moskovitz C, Moses H 3rd, Klawans HL: Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 1978;135:669-675.
10. Papapetropoulos S, Argyriou AA, Ellul J: Factors associated with drug-induced visual hallucinations in Parkinson's disease. J Neurol 2005;252:1223-1228.
11. Fenelon G, Mahieux F, Huon R, Ziegler M: Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000;123:733-745.
12. Goetz CG, Stebbins GT: Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993;43:2227-2229.
13. Papapetropoulos S, Gonzalez J, Lieberman A, Villar JM, Mash DC: Dementia in Parkinson's disease: a post-mortem study in a population of brain donors. Int J Geriatr Psychiatry 2005; 20:418-422.